A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer

Abstract The objective of this multicenter, single‐arm trial (ChiCTR1900022293) was to explore the efficacy and safety of neoadjuvant therapy with epirubicin, cyclophosphamide, and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib (ECPy‐THPy) in the treatment of patients with stage II–III...

Full description

Bibliographic Details
Main Authors: Qiyun Shi, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Shushu Wang, Yan Liang, Ying Hu, Minghao Wang, Lin Ren, Guozhi Zhang, Xuanni Tan, Long Yuan, Junze Du, Xiujuan Wu, Mengyuan Wang, Hongying Che, Pengwei Lv, Dejie Chen, Jinhui Hu, Qiuyun Li, Yanwu Zhang, Kunxian Yang, Yuan Zhong, Chuang Chen, Zemin Zhou, Liyuan Qian, Jingwei Zhang, Mingde Ma, Yi Sun, Yi Zhang, Jun Jiang
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:MedComm
Subjects:
HER2‐positive breast cancer
multicenter study
neoadjuvant therapy
pyrotinib
trastuzumab
Online Access:https://doi.org/10.1002/mco2.435

Internet

https://doi.org/10.1002/mco2.435

Similar Items